Despite decades of research, the clinical efficacy of peritoneal dialysis (PD) remains enigmatic. We may wonder why the modality fail in some patients but perhaps the more proper question would be, why it works in so many? We know that the contribution of residual renal function (RRF), more so than in hemodialysis, is critically important to the well-being of many of the patients. Unique features of the modality include the relatively low volume of dialysate fluid needed to provide effective uremic control and the disproportionate tendency for both hypokalemia and hypoalbuminemia, when compared to hemodialysis. It is currently believed that most uremic toxins are generated on the interface of human and bacterial structures in the gastrointestinal tract, the intestinal biota. PD offers disproportionate removal of these toxins upon "first-pass", i.e., via PD fluid exchanges before reaching the systemic circulation beyond the gastrointestinal compartment. Studies examining the net removal gradient of protein-bound uremic toxins during PD are scarce, whereas RRF receives considerably more attention without effective interventions being developed to preserve it. We propose an alternative view on PD, emphasizing the modality's compartmental nature, both for its benefits and the limitations.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.mehy.2017.09.005 | DOI Listing |
Kidney360
January 2025
Lund University, Skåne University Hospital, Clinical Sciences Lund, Department of Nephrology, Lund, Sweden.
Background: Water retention, ultrafiltration insufficiency, and metabolic complications due to abnormally high glucose concentrations are still common problems in patients treated with peritoneal dialysis. Phloretin, a nonselective inhibitor of facilitative glucose transporter channels (GLUT), has shown to improve water transport and lower glucose absorption in experimental peritoneal dialysis. However, the dose-response relationship remains unknown, and we therefore performed a dose-response study to elucidate the pharmacodynamic properties of intra-peritoneal phloretin therapy.
View Article and Find Full Text PDFCureus
December 2024
Nephrology, Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, PRT.
Exit-site infections (ESIs) of peritoneal dialysis catheters can cause serious complications if not promptly treated. Uncommon pathogens like are infrequently associated with these infections. We report a 26-year-old woman with end-stage renal disease due to Alport syndrome, presenting with recurrent purulent discharge and erythema at the Tenckhoff catheter exit site.
View Article and Find Full Text PDFAdv Nutr
January 2025
Department of Nephrology, The Scarborough Health Network, Toronto, Ontario, Canada; Kidney Life Sciences Institute, Toronto, Ontario, Canada.
Managing diabetes in patients on peritoneal dialysis (PD) is challenging due to the combined effects of dietary glucose, glucose from dialysate, and other medical complications. Advances in technology that enable continuous biological data collection are transforming traditional management approaches. This review explores how multi-omics technologies and artificial intelligence (AI) are enhancing glucose management in this patient population.
View Article and Find Full Text PDFBackground Dry weight management in dialysis patients is crucial but often subjective, primarily based on symptoms. Due to continuous fluid removal in peritoneal dialysis (PD) and intermittent ultrafiltration in hemodialysis (HD), symptom-based assessments may be biased, leading to varying results. Surprisingly, no direct comparison of dry weight changes between PD and HD has been conducted.
View Article and Find Full Text PDFPediatr Int
January 2025
Department of Pediatrics, Dokkyo Medical University, Tochigi, Japan.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!